drugset / Trial / NCT00611637
CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease
Phase 1
Terminated
2 enrolled
H. Kim Lyerly
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-label
Summary
The purpose of this study is to determine the safety and feasibility of CMV specific, T cell adoptive immunotherapy in patients who have undergone allogeneic stem cell transplantation for malignant disease.
Timeline
- Start
- 2005-08
- Primary completion
- 2008-02
- Completion
- 2008-06
Outcome
Outcome not reported
Stopped (Enrollment): “low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CMVpp65 Specific T-cells | Cell therapy | 100000 cells/kg | Other |